Stockholders' Equity Note Disclosure [Text Block] | 11. Stockholders’ Equity Authorized 2,000,000 18,000,000 0.001 Year ended January 31, 2018 i) On February 10, 2017, the Company entered into an At the Market Offering Agreement (the “Agreement”) with Maxim Group LLC (“Maxim”), as amended on March 30, 2017, pursuant to which the Company could sell from time to time, up to an aggregate of $ 5,500,000 Under the terms of the Agreement, Maxim was entitled to a commission at a fixed rate of 3.5 Year ended January 31, 2018 During the year ended January 31, 2018 pursuant to and under the terms of the Agreement, as amended, the Company issued an aggregate of 2,189,052 5,499,723 5,307,233 Year ended January 31, 2017 ii) On January 12, 2017, the Company entered into a Securities Purchase Agreement with certain investors providing for the issuance and sale by the Company of 1,879,811 1.04 1,955,003 288,462 1,592,175 iii) On January 12, 2017, in connection with the Offering, the Company issued 202,520 224,000 4,281 2014 Stock Option Plan On June 6, 2014, the Company’s board of directors approved a 2014 Long-Term Incentive Plan (the “2014 Plan”), which provides for the grant of stock options, restricted shares, restricted share units and performance stock and units to directors, officers, employees and consultants of the Company. Stockholder approval of the plan was obtained on August 21, 2014. The maximum number of our common stock reserved for issue under the plan is 2,750,000 The 2014 Plan is administered by the board of directors, except that it may, in its discretion, delegate such responsibility to a committee of such board. The exercise price will be determined by the board of directors at the time of grant. Stock options may be granted under the 2014 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2014 Plan. At January 31, 2018, 509,601 759,601 Stock Based Compensation Number Weighted Average Weighted Average Grant Date of Options Exercise Price Fair Value Outstanding at January 31, 2016 2,191,274 $ 5.12 $ 7.86 Expired (93,875) $ 5.19 Forfeited (70,000) $ 5.12 Granted 260,000 $ 2.21 $ 1.41 Outstanding at January 31, 2017 2,287,399 $ 4.78 $ 6.96 Expired (15,000) $ 10.00 9.37 Granted 1,200,000 $ 2.14 $ 0.89 Outstanding at January 31, 2018 3,472,399 $ 3.85 $ 4.85 Exercisable at January 31, 2018 3,316,167 $ 3.87 Number Exercise Expiry Number 1,250 $ 10.00 February 1, 2018 1,250 3,750 $ 10.00 May 1, 2018 3,750 2,000 $ 10.00 April 1, 2019 2,000 25,000 $ 10.00 July 30, 2022 25,000 1,536,750 $ 5.12 June 6, 2024 1,536,750 25,000 $ 6.00 June 10, 2024 25,000 37,500 $ 4.48 February 3, 2025 25,000 37,500 $ 4.48 February 25, 2025 25,000 6,250 $ 4.80 July 6, 2025 6,250 337,399 $ 4.40 August 18, 2025 281,167 10,000 $ 2.50 February 2, 2026 10,000 100,000 $ 2.50 November 1, 2026 100,000 150,000 $ 2.00 November 1, 2026 75,000 1,200,000 * $ 2.14 March 13, 2021 1,200,000 3,472,399 3,316,167 The aggregate intrinsic value of stock options outstanding is calculated as the difference between the exercise price of the underlying awards and the fair value of the Company’s common stock. At January 31, 2018, the aggregate intrinsic value of stock options outstanding is $Nil and exercisable is $Nil (2 0 During the year ended January 31, 2018, the Company recognized $ 2,478,633 5,452,931 202,411 2018 2017 Expected term of stock option (years) (1) 8.75 9.71 Expected volatility (2) 75.60 % 75.78 % Stock price at date of issuance $ 1.43 $ 0.99 Risk-free interest rate 2.69 % 2.29 % Dividend yields 0.00 % 0.00 % (1) As the Company has insufficient historical data on which to estimate the expected term of the options, the Company has elected to apply the short-cut method to determine the expected term under the guidance of Staff Accounting Bulletin No. 110 (“SAB 110”). (2) As the Company has insufficient historical data on which to estimate expected future share price volatility, the Company has estimated expected share price volatility based on the historical share price volatility of comparable entities. Share Purchase Warrants At January 31, 2018, the Company had 1,212,302 share purchase warrants outstanding as follows: Number Exercise Price Expiry Date 3,750 $ 10.00 August 10, 2018 60,001 $ 6.00 April 4, 2019 555,968 $ 6.00 June 10, 2019 155,052 $ 3.00 June 10, 2019 168,883 $ 6.00 July 8, 2019 29,343 $ 3.00 July 8, 2019 24,625 $ 8.00 October 23, 2019 137,180 $ 4.80 December 23, 2020 15,000 $ 4.80 July 6, 2022 62,500 $ 5.11 September 1, 2022 1,212,302 The Company recognized stock-based compensation expense of $ 41,159 104,284 On December 7, 2017, the Company paid $ 50,000 365,688 36,569 Number of Weighted Average Warrants Exercise Price Outstanding at January 31, 2016 1,645,198 $ 5.27 Expired (18,188) 4.00 Outstanding at January 31, 2017 1,627,010 $ 5.29 Repurchased (402,257) 4.80 Expired (12,451) 10.00 Outstanding at January 31, 2018 1,212,302 $ 5.40 |